Assignee
HALOZYME INC
US·51 granted patents·28 pending applications·925 citations·filing 2001–2025
Top patents by PatentIndex Score
79 records- 0199US7871607B2Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanasesHALOZYME INC·Filed 2005·Granted Jan 18, 2011·128 cites·32 claims
- 0299US7846431B2Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanasesHALOZYME INC·Filed 2010·Granted Dec 7, 2010·89 cites·18 claims
- 0399US7829081B2Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanasesHALOZYME INC·Filed 2010·Granted Nov 9, 2010·92 cites·21 claims
- 0499US7767429B2Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereofHALOZYME INC·Filed 2004·Granted Aug 3, 2010·250 cites·52 claims
- 0598US11066656B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2020·Granted Jul 20, 2021·30 cites·25 claims
- 0698US11041149B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2020·Granted Jun 22, 2021·32 cites·17 claims
- 0798US10865400B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2016·Granted Dec 15, 2020·25 cites·18 claims
- 0898US10016491B2Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanasesHALOZYME INC·Filed 2015·Granted Jul 10, 2018·28 cites·28 claims
- 0997US12104185B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Oct 1, 2024·2 cites·11 claims
- 1097US12091692B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2021·Granted Sep 17, 2024·3 cites·40 claims
- 1197US12077791B2PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereofHALOZYME INC·Filed 2023·Granted Sep 3, 2024·1 cites·10 claims
- 1297US12018298B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Jun 25, 2024·1 cites·22 claims
- 1397US11952600B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Apr 9, 2024·2 cites·21 claims
- 1497US10588983B2Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanasesHALOZYME INC·Filed 2018·Granted Mar 17, 2020·27 cites·10 claims
- 1597US9211315B2Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanasesHALOZYME INC·Filed 2014·Granted Dec 15, 2015·36 cites·29 claims
- 1697US8343487B2Large-scale production of soluble hyaluronidaseHALOZYME INC·Filed 2012·Granted Jan 1, 2013·48 cites·18 claims
- 1796US10286044B2Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereofHALOZYME INC·Filed 2017·Granted May 14, 2019·14 cites·22 claims
- 1896US7718428B2Myeloid colony stimulating factor and uses thereofHALOZYME INC·Filed 2006·Granted May 18, 2010·27 cites·3 claims
- 1996US7544499B2Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereofHALOZYME INC·Filed 2003·Granted Jun 9, 2009·49 cites·17 claims
- 2094US12264345B1PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Apr 1, 2025·0 cites·17 claims
- 2193US12195773B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Jan 14, 2025·0 cites·15 claims
- 2293US9562223B2Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)HALOZYME INC·Filed 2014·Granted Feb 7, 2017·10 cites·24 claims
- 2393US2025051747A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Application pending·0 cites
- 2492US12037618B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2021·Granted Jul 16, 2024·1 cites·40 claims
- 2592US11723959B2Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptideHALOZYME INC·Filed 2020·Granted Aug 15, 2023·2 cites·13 claims
- 2692US2025154488A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Application pending·0 cites
- 2791US10898551B2Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereofHALOZYME INC·Filed 2019·Granted Jan 26, 2021·2 cites·41 claims
- 2891US10137104B2Combination therapy with an anti-hyaluronan agent and therapeutic agentHALOZYME INC·Filed 2017·Granted Nov 27, 2018·9 cites·30 claims
- 2990US12371685B2PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereofHALOZYME INC·Filed 2023·Granted Jul 29, 2025·0 cites·10 claims
- 3090US12152262B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Nov 26, 2024·0 cites·13 claims
- 3190US2025041521A1Prefilled syringe injectorHALOZYME INC·Filed 2024·Application pending·0 cites
- 3289US2025222078A1Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditionsHALOZYME INC·Filed 2024·Application pending·0 cites
- 3389US2023321203A1SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOFHALOZYME INC·Filed 2023·Application pending·0 cites
- 3488US12123035B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 22, 2024·0 cites·34 claims
- 3588US12110520B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 8, 2024·0 cites·35 claims
- 3688US12104184B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 3788US12060590B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Aug 13, 2024·0 cites·35 claims
- 3888US12054758B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Aug 6, 2024·0 cites·40 claims
- 3988US12049652B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Jul 30, 2024·0 cites·40 claims
- 4088US2023287381A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Application pending·0 cites
- 4184US10265410B2Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effectsHALOZYME INC·Filed 2016·Granted Apr 23, 2019·4 cites·35 claims
- 4282US12551539B2Hyaluronidase enzyme formulations for high volume administrationHALOZYME INC·Filed 2024·Granted Feb 17, 2026·0 cites·20 claims
- 4382US12544429B2Hyaluronidase enzyme formulations for high volume administrationHALOZYME INC·Filed 2024·Granted Feb 10, 2026·0 cites·20 claims
- 4482US2025197835A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4582US2025197832A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4682US2025197834A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4782US2025197833A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4880US12558404B2Hyaluronidase enzyme formulations for high volume administrationHALOZYME INC·Filed 2024·Granted Feb 24, 2026·0 cites·15 claims
- 4980US12178860B2Hyaluronidase enzyme formulations for high volume administrationHALOZYME INC·Filed 2023·Granted Dec 31, 2024·0 cites·12 claims
- 5080US7538097B2Inhibition of antigen presentation with poorly catabolized polymersHALOZYME INC·Filed 2001·Granted May 26, 2009·8 cites·9 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →